EGFR and non-small cell lung carcinoma: Multiple FDA approved drugs, such as Gefitinib and Lapatinib, are effective in EGFR-related non-small-cell lung cancer and several other cancers (Rawluk and Waller, 2018; Voigtlaender et al., 2018).